Which of the following statements is true about prasugrel?

Correct Answer: A. It is a pro drug

Prasugrel is a third-generation thienopyridine antiplatelet agent that is fundamentally a prodrug—it requires hepatic metabolism to generate its active metabolite. Unlike clopidogrel (which undergoes two-step activation via CYP3A4 and CYP2C19), prasugrel is activated primarily by esterase-mediated hydrolysis followed by CYP3A4 and CYP2D6 oxidation to form its active thiol metabolite. This active form irreversibly inhibits the P2Y12 ADP receptor on platelets, preventing platelet aggregation. The prodrug nature is clinically significant because it explains prasugrel's more predictable pharmacokinetics and reduced inter-individual variability compared to clopidogrel. In Indian clinical practice, prasugrel is increasingly used in acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI) settings where rapid, consistent platelet inhibition is critical. The prodrug activation mechanism is the defining pharmacological characteristic that distinguishes prasugrel from other antiplatelet agents.

Why the other options are wrong

B. It is 10 times less potent than clopidogrel — This is factually inverted. Prasugrel is more potent than clopidogrel—it achieves faster and more consistent platelet inhibition. Clinical trials (TRITON-TIMI 38) demonstrated prasugrel's superior efficacy in reducing stent thrombosis and cardiovascular events in ACS patients. The trap here is confusing potency with frequency of dosing; prasugrel's loading dose is 60 mg (vs clopidogrel's 600 mg), but this reflects its higher intrinsic activity, not lower potency. C. Omeprazole interferes in its activation to an active metabolite — This is a clopidogrel-specific problem, not prasugrel. Omeprazole (a CYP2C19 inhibitor) significantly reduces clopidogrel's activation and antiplatelet effect—a major concern in Indian practice where PPI co-prescription is common in ACS patients. Prasugrel's activation is less dependent on CYP2C19, making it relatively unaffected by omeprazole. NBE exploits the well-known clopidogrel-PPI interaction to trap students into selecting this option. D. It acts as a P2Y12 agonist — This is mechanistically incorrect. Prasugrel acts as a P2Y12 antagonist (inhibitor), not an agonist. It irreversibly blocks the P2Y12 ADP receptor, preventing platelet activation and aggregation. An agonist would activate the receptor and promote thrombosis—the opposite of the desired antiplatelet effect. This is a classic NBE trap using terminology reversal to catch students who know prasugrel affects P2Y12 but confuse the direction of action.

High-Yield Facts

Mnemonics

PRO-drug PRasugrel PRO = PRasugrel is a PROdrug. Requires hepatic activation. Remember: Pro = needs processing before action. P2Y12 Antagonist (not Agonist) Prasugrel BLOCKS P2Y12 (like all thienopyridines). Antagonist = Anti-platelet. Agonist would cause thrombosis—opposite of what we want.

NBE Trap

NBE pairs prasugrel with "agonist" (option D) to trap students who correctly recall that prasugrel targets P2Y12 but confuse the direction of action. Additionally, option B inverts the potency relationship, exploiting confusion between prasugrel's lower dose (60 mg loading) and its actual higher potency. Option C transfers the well-known clopidogrel-omeprazole interaction to prasugrel, testing whether students understand the mechanistic difference in their metabolic pathways.

Clinical Pearl

In Indian ACS practice, prasugrel is increasingly preferred over clopidogrel in PCI-eligible patients because its prodrug activation is more reliable and unaffected by the CYP2C19 polymorphisms common in Indian populations. However, bleeding risk (especially in elderly/low-weight patients) and contraindication in prior stroke limit its use—clopidogrel remains first-line in many resource-limited settings.

_Reference: KD Tripathi Pharmacology Ch. 19 (Antiplatelet Drugs); Harrison Ch. 318 (Acute Coronary Syndromes)_